A new review from the Cochrane Database of Systematic Reviews confirms that antidepressants can effectively reduce symptoms of generalized anxiety disorder (GAD) in clinical trials. However, there is ...
Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for depression and neurological disorders. The licensing agreement gives Biogen ...
Glyph drugs are designed to be absorbed through the lymphatic system, avoiding the liver, much like dietary fats. There has been a lot of interest in using allopregnanolone to treat depression ...
Jan. 27, 2025 — A brain rhythm working in tandem with the body's natural sleep-wake cycle may explain why bipolar patients alternate between mania and depression, according to new research.
Takeda is taking back the home license for a phase 3-stage depression drug as part of an ... Not all of the drugs covered by Takeda’s original pact with Neurocrine have been as successful ...